Literature DB >> 5150308

[Drying of cirrhotic ascites by continuous intravenous reinjection of concentrated ascitic fluid].

V G Lévy, Y Hecht, H Georgacopoulos, P Hadchouel, J P Touboul, A Sausse, A Granger, A Stern, J Caroli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5150308

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN： 0003-410X


× No keyword cloud information.
  5 in total

1.  Treatment of ascites by reinfusion of concentrated peritoneal fluid--review of 318 procedures in 210 patients.

Authors:  V G Lévy; P Opolon; N Pauleau; J Caroli
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

2.  Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.

Authors:  Rumi Hanada; Naosuke Yokomichi; Chihiro Kato; Kazumi Miki; Sachiko Oyama; Tatsuya Morita; Ryoko Kawahara
Journal:  Support Care Cancer       Date:  2017-11-22       Impact factor: 3.603

3.  Concentration-reinfusion (CR) of ascitic of ascitic fluid in the treatment of decompensated liver cirrhosis with diuretic-resistant ascites.

Authors:  E Ventura; M L Zeneroli
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

4.  Treatment of resistant ascites by continuous ultrafiltration--reinfusion of ascitic fluid.

Authors:  J P Villeneuve; C Thuot; D Marleau; J G Joly; P M Huet; A Viallet
Journal:  Can Med Assoc J       Date:  1977-12-03       Impact factor: 8.262

5.  Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites.

Authors:  Naosuke Yokomichi; Kengo Imai; Masaki Sakamoto; Masashi Horiki; Toshihiro Yamauchi; Satoru Miwa; Satoshi Inoue; Yu Uneno; Hidekazu Suzuki; Toru Wada; Yuri Ichikawa; Tatsuya Morita
Journal:  BMC Cancer       Date:  2022-02-28       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.